<div id="readability-page-1"><p>William Blair analyst Myles Minter has maintained their bullish  stance on <span>ALNY</span> stock, giving a Buy rating yesterday.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Myles Minter has given his Buy rating due to a combination of factors, including Alnylam’s strong quarterly execution and reaffirmed long‑term outlook. The company delivered revenue and earnings that exceeded both his projections and Street expectations, driven largely by robust growth in the TTR franchise, particularly Amvuttra’s continued uptake in ATTR-CM, which supports confidence in the full-year revenue targets.</p> <p>Minter also highlights management’s unchanged 2026 guidance, which points to multibillion-dollar product revenue and disciplined expense control, reinforcing a compelling growth and profitability trajectory. In addition, accelerated enrollment and expansion of the Phase III TRITON trial for nucresiran, while keeping the anticipated 2030 launch timeline intact, strengthens his conviction in the company’s late-stage pipeline and future value creation potential. </p> <p>Minter covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, Immunic, and Moderna. According to TipRanks, Minter has an average return of <span>34.6%</span> and a 59.09% success rate on recommended stocks. </p> <p>In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $510.00 price target.</p></div>

ALNY

SBIO

<p>William Blair analyst Myles Minter has reiterated a Buy rating on Alnylam Pharmaceuticals (ALNY) following strong quarterly results that exceeded expectations. The positive outlook is supported by robust growth in the TTR franchise, particularly Amvuttra, and management's reaffirmed 2026 guidance indicating significant product revenue. Minter also noted the accelerated enrollment in the Phase III TRITON trial for nucresiran, maintaining the 2030 launch timeline. H.C. Wainwright also issued a Buy rating with a $510 price target.</p>

Tip Ranks

Alnylam Pharma

VG Health

ALPS Medical Breakthrough

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Ark Genomic Revolution ETF

Direxion Daily Biotech Top 5 Bull 2X ETF

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

Dianthus Therapeutics

Immunic

Moderna

Myles Minter Reiterates Buy on Alnylam After Strong Beat, Reaffirmed 2026 Outlook, and Advancing TRITON Phase III Pipeline